CA
SPRO icon

CoreCap Advisors’s Spero Therapeutics SPRO Stock Holding History

CoreCap Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$36 – 3206
2025
Q1 		$36 Hold
50
– – ﹤0.01% 3095
2024
Q4 		$52 Sell
50
-142
-74% -$169 ﹤0.01% 2798
2024
Q3 		$257 Hold
192
– – ﹤0.01% 2461
2024
Q2 		$250 Buy
192
+50
+35% +$75 ﹤0.01% 1496
2024
Q1 		$244 Buy
+142
New +$223 ﹤0.01% 2396
2022
Q4 		$246 Buy
+142
New +$265 ﹤0.01% 2254
2022
Q3 		– Sell
-142
Closed – – 1862
2022
Q2 		$0 Buy
+142
New +$413 ﹤0.01% 2263
2022
Q1 		– Sell
-142
Closed -$2K – 1864
2021
Q4 		$2K Buy
+142
New +$2.25K ﹤0.01% 1995

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

CoreCap Advisors's SPRO Position: Q2 2025 in Review

CoreCap Advisors sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 50 shares — an estimated $36 sold.

CoreCap Advisors first reported a position in SPRO in Q4 2021 and held it in 8 quarters. The position peaked at $2K in Q4 2021. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • CoreCap Advisors reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 50 Spero Therapeutics shares in Q2 2025, an estimated $36.
  • CoreCap Advisors first reported a position in Spero Therapeutics in Q4 2021 and held it in 8 quarters.
  • CoreCap Advisors's Spero Therapeutics position peaked at $2K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.